Schedule 13D ownership disclosure

Prelude Therapeutics, Inc.

Security class unavailable · CUSIP: 74065P101

Event date: 2023-05-22

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
15,716,642
Percent of class
28.6000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-23-000625
Form type
SC 13D/A
Filer
ORBIMED ADVISORS LLC
CIK
CIK 1055951
Filed
May 24, 2023
Reporting period
May 22, 2023
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub